Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

Inclusion Criteria

• •History of HTN and one of the following at BOTH screening and pre-randomization:
• •1. SBP \>105 mm Hg on antihypertensive medication.
• •2. SBP \>/= 140 mm Hg and NOT on antihypertensive medication.
• •NYHA class I-III heart failure and with reduced ejection fraction \</= 40%, as determined by any local measurement made within the past 12 months using echocardiography, MUGA, CT scanning, MRI, ventricular angiography or single-photon emission computed tomography (SPECT), provided no subsequent measurement above 40%. Patients who have had an intervening medical event (e.g. myocardial infarction) or procedure (e.g. revascularization, cardiac resynchronization), must have a reassessment of EF ≥ 3 months following the event to ensure that eligibility criteria are still met.
• •On stable doses of treatment with guideline-directed therapy, other than ACEis and ARBs prior to randomization.
• •1. If the patient is currently taking an ACEi, a 36-hour washout is required prior to randomization (Visit 2).
• •2. If the patient is currently taking an ARB, they must discontinue the ARB before initiation of study treatment however washout is not required.
• •On an optimal medical regiment of diuretics and background medications to effectively treat co-morbidities such as HTN, DM, and coronary artery disease.